Clinical Trials Logo

Clinical Trial Summary

Background: Duchenne muscular dystrophy (DMD) is an X chromosome recessive hereditary disease and mainly characterized by progressive muscle weakness and atrophy. Glucocorticoid is the only proven effective medicine,while side effects limit its use. Recent studies have shown that the vascular density in the DMD patients' muscle is decreased,so muscle are in ischemic and anoxic. Remote ischemic preconditioning(RIPC) can improve the capable of resistanting ischemia and hypoxia and maybe a potential therapy for DMD patients.

Methods: 100 patients (aged 2 to 6 years)will be divided into two groups(treatment and control groups) randomly. Treatment group will receive an RIPC stimulus (inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals) while control group will receive a similar stimulus (inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals). Serum kinase level ,Blood levels of myoglobin, Evaluation of motor function(Four steps test;6-minute walking test) and MRI of lower limbs)at 0 days, 3 days, 3months ,6months.

Purpose:

1. To evaluate the safety and tolerability of remote ischemic preconditioning for DMD patients

2. To identify the effectiveness of remote ischemic preconditioning for DMD patients.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02614820
Study type Interventional
Source General Hospital of Chinese Armed Police Forces
Contact wu shiwen, Dr.
Phone 13910238117
Email wu_shiwen@yahoo.com
Status Recruiting
Phase N/A
Start date November 2015
Completion date December 2016

See also
  Status Clinical Trial Phase
Terminated NCT02814019 - A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Phase 3
Completed NCT01478022 - To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 Phase 1
Completed NCT00654784 - Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy Phase 2
Withdrawn NCT02036463 - A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy Phase 2
Completed NCT02255552 - Study of Eteplirsen in DMD Patients Phase 3
Completed NCT01982695 - Cardiomyopathy in DMD: Lisinopril vs. Losartan N/A
Recruiting NCT05516745 - E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home" N/A
Completed NCT02420379 - Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Phase 2
Active, not recruiting NCT05135663 - Extension Study of NS-089/NCNP-02 in DMD Phase 2
Completed NCT01380964 - Research of Biomarkers in Duchenne Muscular Dystrophy Patients N/A
Completed NCT05990608 - Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
Recruiting NCT04322357 - Twice Weekly Steroids and Exercise as Therapy for DMD Phase 2
Not yet recruiting NCT06392724 - A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy. Early Phase 1
Completed NCT01540409 - Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Phase 2
Terminated NCT04184882 - A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) Phase 1
Terminated NCT04254172 - A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
Recruiting NCT05524883 - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Phase 1/Phase 2
Completed NCT01761292 - A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Phase 1/Phase 2